US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
pharma · Schizophrenia · Narcolepsy Type 1
Alkermes Pharma Ireland
Alkermes Pharma Ireland drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Dublin, USA HQ
27 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Dublin, USA
- Employees
- 27
- Programs
- 1
- Drugs
- 1
- Patents
- 1
Alkermes Pharma Ireland pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Alkermes Pharma Ireland drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.